Full-Time

Lead Director

Mobile Engineering

Deadline 9/20/26
CVS Health

CVS Health

10,001+ employees

Healthcare, insurance, PBM, and retail pharmacy

Compensation Overview

$144.2k - $288.4k/yr

+ Bonus + Commission + Short-term incentive + Equity award

Company Historically Provides H1B Sponsorship

Colorado, USA

Remote

Bachelor's

Category
Engineering Management (1)
Required Skills
Kotlin
Product Management
iOS/Swift
Observability

Get referred to CVS Health

See people who can refer or advise you

Requirements
  • At least 10 years of experience in software engineering, including building and delivering modern mobile applications.
  • At least 5 years of experience partnering with Product, Design, and Platform teams in large, matrixed organizations.
  • A bachelor's degree or equivalent experience, defined as a high school diploma plus four years of relevant experience.
Responsibilities
  • Lead and develop engineering managers and staff-level engineers, fostering a culture of trust, accountability, and continuous improvement.
  • Own delivery outcomes for mobile initiatives, ensuring commitments are based on realistic capacity, clear dependencies, and sound technical plans.
  • Partner with Product and Design leaders to align on priorities, scope, and sequencing, translating strategy into executable plans.
  • Guide technical direction across the technology stack, including Jetpack Compose, Kotlin, SwiftUI, and Swift, balancing innovation with stability.
  • Drive operational excellence through strategic planning, observability, security, and post-incident learning.
  • Anticipate and manage delivery risk in complex, cross-team environments with shared services and dependencies.
  • Support hiring, onboarding, and talent development, while ensuring teams are structured to scale sustainably.
  • Represent mobile engineering in executive and cross-functional forums, communicating clearly, calmly, and with credibility.
  • Champion inclusive, accessible, and member-centric digital experiences aligned with CVS Health values.
Desired Qualifications
  • Demonstrated ability to balance technical excellence, delivery accountability, and people leadership.
  • Comfort operating with ambiguity and evolving priorities while maintaining clarity for teams.
  • Experience evaluating, adopting, and scaling emerging technologies, including artificial intelligence-enabled tools and capabilities, to improve engineering productivity, product quality, and team effectiveness.
  • Strong communication skills, with the ability to explain complex topics to technical and non-technical audiences.
  • Experience working in regulated or highly available environments, such as healthcare, finance, or large-scale consumer platforms.
  • Experience supporting large-scale redesigns, platform modernization, engineering processes, and system optimization.
  • Familiarity with observability, experimentation, and feature-flagging tools.
  • Experience with mentorship, leadership development, and building inclusive teams.
  • Collaboration skills to ideate solutions that are sufficient and feasible for business leads and technical teams.
  • Organizational, analytical, problem-solving, strategic-thinking, and time-management abilities.
  • Experience optimizing application performance, scalability, and usability.
  • Ability to implement new ideas and approaches using various technologies.
  • A self-starting and inquisitive approach.
  • Experience with agile development; SAFe Agile experience is preferred.

CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Woonsocket, Rhode Island

Founded

1963

Get referred to CVS Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 CVS raised adjusted EPS guidance to $7.90-$8.10 and revenue to $414 billion.
  • Walgreens plans roughly 1,200 U.S. store closures through 2027, sending prescription volume to CVS.
  • Teresa Heitsenrether joined the board September 2026, strengthening CVS’s data and digital execution focus.

What critics are saying

  • May 2026 340B lawsuits from Mount Sinai, Michigan, and Kansas attack Caremark’s remittance model.
  • CVS disclosed 2027 Caremark membership declines and continued 340B pressure on August 5, 2026.
  • If courts restrict 340B spreads or rebate flows, CVS loses a core profit engine.

What makes CVS Health unique

  • CVS Health combines Aetna, Caremark, and 9,000 pharmacies across one U.S. customer funnel.
  • August 5, 2026 results showed integrated pricing, insurance, and pharmacy scale outperformed standalone peers.
  • The August 2026 Eli Lilly collaboration embeds Zepbound and Foundayo access inside CVS channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Company Equity

Wellness Program

Professional Development Budget

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Sep 14th, 2026
CVS Health up 32% in a year: is it time to buy the stock?

CVS Health shares have declined 2.1% over the past three months, prompting investors to consider whether now is an opportune time to buy. The healthcare giant, which operates approximately 9,000 retail pharmacy locations and serves more than 35 million people through its health insurance business, reported second-quarter revenue of $106 billion, up 7.3% year-over-year. Adjusted earnings per share rose 43% in the same period. The company offers a dividend yield of 2.8%, with its annual payout increasing from $2 in 2021 to $2.66 per share recently. Shares currently trade at $95, with one analyst setting a price target of $120. The stock's forward price-to-earnings ratio of 11 sits slightly above its five-year average of 10.

Yahoo Finance
Sep 13th, 2026
US health insurers rebound as medical costs stabilise, analysts predict 16% earnings growth through 2030

The health insurance industry may have recovered from high medical costs, with analysts predicting strong growth through 2030. Morningstar forecasts 16% annual earnings per share growth for major insurers, above the industry's typical low-double-digit target. Health insurers are improving profitability by raising rates to cover increased medical utilisation. UnitedHealth Group reported over $5 billion in second-quarter net income, with its medical care ratio falling to 86.7% from 89.4% year-over-year. The outlook also improved for pharmacy benefit management operations at companies like UnitedHealth, CVS Health, and Cigna. Despite increased regulatory scrutiny, the "big three" PBMs maintain strong competitive positions. Third-quarter earnings reports next month should provide further clarity on the industry's financial health.

Yahoo Finance
Sep 12th, 2026
CVS quietly gains market share as Walgreens closes 1,200 US stores following $10B private equity sale

Walgreens is closing roughly 1,200 of its approximately 8,500 US locations through 2027, with many customers being redirected to nearby CVS pharmacies. The pattern is reshaping suburban pharmacy markets without direct competition. In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the 124-year-old chain private for the first time. Mike Motz was named chief executive, replacing Tim Wentworth. CVS is gaining market share without active expansion efforts. Federal and state rules require orderly prescription transfers when pharmacies close, often directing patients to the nearest CVS location. CVS and Walgreens together now handle nearly 40% of all US retail prescription sales. CVS benefits from owning Caremark, a dominant pharmacy benefit manager, providing vertical integration advantages.

Yahoo Finance
Aug 28th, 2026
CVS stock down 12% in a month despite 34% annual gain, faces 2027 headwinds

CVS Health stock has declined 12.3% over the past month, sitting about 15% below its 52-week high, though it remains up 34% over the trailing twelve months. The company's revenue reached approximately $415 billion, up 7.4% year-over-year. Management raised its full-year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10. For 2027, the company anticipates membership declines at Caremark and continued 340B programme pressure, offset by Aetna's recovery, which added over $2 billion in adjusted operating income in the first half of 2026. Management considers a 2027 adjusted EPS outlook of at least $8.44 reasonable. Historically, CVS has experienced varied recovery periods following market downturns, with some rebounds taking years rather than months.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.